Pharmabcine Is A Clinical Stage Public Company Developing Next Generation Igg Based Therapeutics To Treat Cancerneovascular Eye Diseasesand Vascular Related Unmet Needs Pharmabcine Has Its Own Huphage Library And Innovative Selection Systemthis Technology Provides Therapeutic Antibodies For A Wide Spectrum Of Indications In Oncologyimmuno Oncologyophthalmologypulmonology Etcpharmabcine S Advanced 3G Expression System Accommodates High Levels Of Antibody Production And Steady Reproducibilitywith These Cutting Edge Technology Platformsit Provides State Of The Art Antibody Generation Services Pharmabcine Has Focused On The Development Of Novel Antibody Therapeutics Since The Company S Foundation In 2008 And Laid The Groundwork For The Commercialization Of Olinvacimabpmc 309Pmc 403And Pmc 402We Will Also Become An Innovative Global Biotech Company Through The Development Of Other New Candidates Such As Pmc 005Blpmc 122Pmc 401And Pmc 401S
No conferences found for this company.
| Company Name | Pharmabcine Inc |
| Country |
South Korea
|
| Address | N/A |
| Telephone | N/A |
| N/A |
